Do analysts recommend BFRI or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BFRI or INCR?

InterCure has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.33 -$10.54M -$0.97 N/A InterCure $78.47M 0.63 -$10.37M $0.03 30.24

Do analysts prefer INMB or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, INMB or BFRI?

Biofrontera has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio $50K 1,047.25 -$45.93M -$1.67 N/A Biofrontera $41.71M 0.33 -$10.54M -$0.97 N/A

Is INMB or BFRI more profitable?

INmune Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. INmune Bio's return on equity of -103.03% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Biofrontera -25.66% -515.34% -53.91%

Does the media prefer INMB or BFRI?

In the previous week, INmune Bio had 2 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for INmune Bio and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TIL or BFRI?

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 810.34%. Given Instil Bio's higher possible upside, research analysts clearly believe Instil Bio is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is TIL or BFRI more profitable?

Instil Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Instil Bio's return on equity of -39.76% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Biofrontera -25.66% -515.34% -53.91%

Does the media prefer TIL or BFRI?

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.60 beat Biofrontera's score of 0.00 indicating that Instil Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BFRI or FLNA?

Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor BFRI or FLNA?

In the previous week, Cassava Sciences had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BFRI or MCRB?

Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 223.81%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Biofrontera (BFRI) Competitors

$1.08 +0.03 (+2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 -0.02 (-1.76%)

As of 06:32 PM Eastern

Compare

BFRI vs. INCR, INMB, TIL, FLNA, and MCRB

Should you buy Biofrontera stock or one of its competitors? MarketBeat compares Biofrontera with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biofrontera include InterCure (INCR), INmune Bio (INMB), Instil Bio (TIL), Cassava Sciences (FLNA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Biofrontera compare to InterCure?

Biofrontera (NASDAQ:BFRI) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

In the previous week, Biofrontera had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for InterCure. Biofrontera's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Biofrontera	Neutral
InterCure	Neutral

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biofrontera has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, InterCure has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

InterCure has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. InterCure's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
InterCure	N/A	N/A	N/A

InterCure has higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.33	-$10.54M	-$0.97	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.24

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InterCure beats Biofrontera on 9 of the 14 factors compared between the two stocks.

How does Biofrontera compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

INmune Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. INmune Bio's return on equity of -103.03% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Biofrontera	-25.66%	-515.34%	-53.91%

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biofrontera has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	1,047.25	-$45.93M	-$1.67	N/A
Biofrontera	$41.71M	0.33	-$10.54M	-$0.97	N/A

In the previous week, INmune Bio had 2 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for INmune Bio and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.00 beat INmune Bio's score of -0.61 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

INmune Bio beats Biofrontera on 9 of the 16 factors compared between the two stocks.

How does Biofrontera compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 810.34%. Given Instil Bio's higher possible upside, research analysts clearly believe Instil Bio is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.60 beat Biofrontera's score of 0.00 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Instil Bio has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Instil Bio's return on equity of -39.76% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Biofrontera	-25.66%	-515.34%	-53.91%

Biofrontera has higher revenue and earnings than Instil Bio. Biofrontera is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Biofrontera	$41.71M	0.33	-$10.54M	-$0.97	N/A

Summary

Instil Bio beats Biofrontera on 9 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Cassava Sciences?

Biofrontera (NASDAQ:BFRI) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

In the previous week, Cassava Sciences had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Cassava Sciences and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Cassava Sciences' return on equity of -53.90% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Cassava Sciences	N/A	-53.90%	-34.20%

Biofrontera has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, meaning that its stock price is 173% less volatile than the broader market.

Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biofrontera has higher revenue and earnings than Cassava Sciences. Biofrontera is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.33	-$10.54M	-$0.97	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Summary

Cassava Sciences beats Biofrontera on 8 of the 13 factors compared between the two stocks.

How does Biofrontera compare to Seres Therapeutics?

Biofrontera (NASDAQ:BFRI) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Seres Therapeutics has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.33	-$10.54M	-$0.97	N/A
Seres Therapeutics	$1.15M	44.33	$5.70M	-$5.17	N/A

Seres Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Seres Therapeutics' return on equity of -130.29% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-25.66%	-515.34%	-53.91%
Seres Therapeutics	N/A	-130.29%	-35.35%

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Biofrontera has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 223.81%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Biofrontera had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Seres Therapeutics. Biofrontera's average media sentiment score of 0.00 equaled Seres Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biofrontera	Neutral
Seres Therapeutics	Neutral

Summary

Seres Therapeutics beats Biofrontera on 10 of the 15 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRI vs. The Competition

Export

Metric	Biofrontera	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.82M	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.11	20.79	27.00	24.19
Price / Sales	0.33	320.27	517.85	93.08
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.20	8.17	10.67	6.26
Net Income	-$10.54M	$23.81M	$3.60B	$331.76M
7 Day Performance	1.89%	-1.16%	-0.37%	-1.10%
1 Month Performance	9.42%	2.59%	1.80%	-1.29%
1 Year Performance	24.27%	45.43%	25.50%	18.84%

Biofrontera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRI Biofrontera	0.9723 of 5 stars	$1.08 +2.9%	N/A	+19.0%	$13.82M	$41.71M	N/A	70	Analyst Upgrade
INCR InterCure	0.9367 of 5 stars	$0.95 -3.6%	N/A	-40.1%	$54.13M	$78.47M	31.82	350	Gap Down
INMB INmune Bio	0.811 of 5 stars	$2.07 +2.5%	N/A	-17.8%	$53.70M	$50K	N/A	10	Analyst Upgrade Gap Up
TIL Instil Bio	1.6538 of 5 stars	$7.62 -2.6%	$66.00 +766.1%	-72.2%	$53M	N/A	N/A	410	Positive News
FLNA Cassava Sciences	1.4688 of 5 stars	$1.10 +0.9%	$5.00 +354.5%	-53.8%	$52.66M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRI) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biofrontera (BFRI) Competitors

BFRI vs. INCR, INMB, TIL, FLNA, and MCRB

How does Biofrontera compare to InterCure?

Summary

How does Biofrontera compare to INmune Bio?

Summary

How does Biofrontera compare to Instil Bio?

Summary

How does Biofrontera compare to Cassava Sciences?

Summary

How does Biofrontera compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biofrontera (BFRI) Competitors

BFRI vs. INCR, INMB, TIL, FLNA, and MCRB

How does Biofrontera compare to InterCure?

Does the media favor BFRI or INCR?

Do institutionals & insiders have more ownership in BFRI or INCR?

Which has more volatility and risk, BFRI or INCR?

Is BFRI or INCR more profitable?

Which has better earnings and valuation, BFRI or INCR?

Do analysts recommend BFRI or INCR?

Summary

How does Biofrontera compare to INmune Bio?

Which has more risk & volatility, INMB or BFRI?

Is INMB or BFRI more profitable?

Do institutionals and insiders believe in INMB or BFRI?

Which has stronger earnings & valuation, INMB or BFRI?

Does the media prefer INMB or BFRI?

Do analysts prefer INMB or BFRI?

Summary

How does Biofrontera compare to Instil Bio?

Do analysts prefer TIL or BFRI?

Which has more risk & volatility, TIL or BFRI?

Do insiders and institutionals believe in TIL or BFRI?

Does the media prefer TIL or BFRI?

Is TIL or BFRI more profitable?

Which has preferable valuation and earnings, TIL or BFRI?

Summary

How does Biofrontera compare to Cassava Sciences?

Does the media favor BFRI or FLNA?

Is BFRI or FLNA more profitable?

Which has more volatility and risk, BFRI or FLNA?

Do analysts recommend BFRI or FLNA?

Do institutionals & insiders believe in BFRI or FLNA?

Which has better valuation and earnings, BFRI or FLNA?

Summary

How does Biofrontera compare to Seres Therapeutics?

Which has higher valuation & earnings, BFRI or MCRB?

Is BFRI or MCRB more profitable?

Do institutionals and insiders believe in BFRI or MCRB?

Which has more risk & volatility, BFRI or MCRB?

Do analysts prefer BFRI or MCRB?

Does the media favor BFRI or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI vs. The Competition

Biofrontera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools